Last updated on July 2019

Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)

Brief description of study

Phase 1b: To determine the maximum tolerated dose (MTD) of blinatumomab in combination with pembrolizumab in adult subjects with relapsed or refractory (r/r) DLBCL

Clinical Study Identifier: NCT03340766

Find a site near you

Start Over

Research Site

Heidelberg, Germany
  Connect »